NIH Move To Consolidate Translational Programs Is Not The Big Shakeup It's Made Out To Be, Agency Says
Executive Summary
The National Institutes of Health's proposed National Center for Advancing Translational Sciences reflects neither a shakeup of existing NIH programs nor any intent to create an agency that functions like a drug company, NIH officials say.
You may also be interested in...
NIH Repurposing Of Failed Compounds Could Begin Soon; NCATS Plans Pilots
The National Center for Advancing Translational Science soon may have an agreement with one or more firms to allow research to test abandoned compounds for new uses, NIH Deputy Director for Science, Outreach and Policy Kathy Hudson says. NIH has sought, and will continue to seek, industry input on where NCATS should put its efforts to speed translation of drugs from the bench to the market, she notes.
Tax Incentives For Biomedical Industry Are Focus Of Multiple Bills In Congress
Tax incentives for the life sciences industry have a lot of allies in Congress, but any traction on reforms probably awaits broader movement on major tax or economic legislation
Tax Incentives For Biomedical Industry Are Focus Of Multiple Bills In Congress
Tax incentives for the life sciences industry have a lot of allies in Congress, but any traction on reforms probably awaits broader movement on major tax or economic legislation